Portfoliotracker

Oramed Pharmaceuticals Inc.

ORMP · NASDAQCM · Healthcare Biotechnology 49/100 D

3,900 $
▲ +0,190 (+5,12 %)
Pre-market delayed by 15 min
Price as of 16. 11. 22:00, fetched 17. 11. 13:33
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score49 / 100 Market cap168 mil. $ P/E1,1 Forward P/E-46,4 P/S83,9 P/B0,5 EV/EBITDA– Dividend yield6,41 % FCF yield-1,89 % EPS4,13 $ Net margin0,0 % Return on equity53,5 % Beta1,28 Debt / equity0,00
52-week range 2,25 to 5,47
3-month average volume0,2 M

Finance

Where the revenue goes

Loading the income statement flow…

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.

Website
oramed.com
Country
United States
Fiscal year end
31. 12.
Data since
1. 5. 2007

Explore further

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account